Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patients

BackgroundBy depleting circulating B lymphocytes, rituximab time-dependently suppresses coronavirus disease 2019 (COVID-19) vaccines’ humoral immunogenicity for a prolonged period. The optimal time to vaccinate rituximab-exposed immune-mediated dermatologic disease (IMDD) patients is currently uncle...

Full description

Bibliographic Details
Main Authors: Chutima Seree-aphinan, Yanisa Ratanapokasatit, Poonkiat Suchonwanit, Ploysyne Rattanakaemakorn, Pichaya O-Charoen, Prapaporn Pisitkun, Thanitta Suangtamai, Chavachol Setthaudom, Sonphet Chirasuthat, Kumutnart Chanprapaph
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
rituximab
anti-CD20 antibody
vaccines
COVID-19 vaccines
immunogenicity
immune-mediated dermatologic diseases
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1138765/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1138765/full

Similar Items